Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer

US FDA approval of Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo in relapsed small cell lung cancer based on response rate data marks a breakthrough and gives the drug a lead in a new indication, though it's unclear for how long given that Roche's competing Tecentriq has demonstrated an overall survival benefit in an earlier line of therapy.

The FDA granted accelerated approval for Opdivo (nivolumab) in metastatic small cell lung cancer (SCLC) after progression on platinum-based chemotherapy and at least one other line of therapy on Aug....